Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Medivation Inc. (MDVN): Today's Featured Drugs Laggard

Tickers in this article: MDVN

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Medivation ( MDVN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.9%. By the end of trading, Medivation fell $1.42 (-2.7%) to $50.83 on heavy volume. Throughout the day, 1,897,571 shares of Medivation exchanged hands as compared to its average daily volume of 1,244,300 shares. The stock ranged in price between $49.32-$52.35 after having opened the day at $52.35 as compared to the previous trading day's close of $52.25. Other companies within the Drugs industry that declined today were: Pain Therapeutics ( PTIE), down 49.6%, Durect Corporation ( DRRX), down 34.0%, Affymax ( AFFY), down 24.9% and Optimer Pharmaceuticals ( OPTR), down 14.1%.

  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Medivation, Inc., a biopharmaceutical company, focuses on development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. Medivation has a market cap of $4.0 billion and is part of the health care sector. Shares are up 3.8% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Medivation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Medivation as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and notable return on equity. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow.

On the positive front, Vermillion ( VRML), down 24.7%, Warner Chilcott ( WCRX), down 20.0%, Omeros Corporation ( OMER), down 14.4% and Catalyst Pharmaceutical Partners ( CPRX), down 13.8% , were all gainers within the drugs industry with Celgene Corporation ( CELG) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).